Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need
Observational analysis details poor outcomes and highlights the need for new treatments in patients with relapsed/refractory large B-cell lymphoma after immunotherapy.
Key Points
Median progression-free survival after treatment was only 1.5 months, indicating the poor prognosis for this patient group.
Out of 32 patients, 63% received subsequent therapy after initial treatment with bispecific antibodies.
A significant loss of CD20 expression was observed in 81% of evaluable patients following bispecific antibody therapy.
The findings underscore the urgent need for innovative strategies beyond current treatment options for large B-cell lymphoma.